Effect of Neurexan on the pattern of EEG frequencies in rats
Various medications of natural origin have effectively treated stress-related disorders, such as sleep disturbances and agitated conditions. The efficacy of Neurexan, a multicomponent, low-dose medication, has been demonstrated in observational studies, but its exact mechanism of action has not been determined.
To characterize the effects of Neurexan on the central nervous system, we analyzed the spectral frequencies of field potentials in four rat brain areas after a single oral administration of Neurexan. Different doses of Neurexan were tested within a crossover design, and effects were compared with vehicle control.
Significant effects were observed with 0.5 tablets of Neurexan, predominantly on δ- and θ-waves in the frontal cortex and reticular formation (P < 0.01). In the reticular formation, significant changes of δ- and θ-waves occurred as early as during the first hour after administration. The time course revealed a significant and longer-lasting increase of δ- and θ-waves in the frontal cortex and reticular formation, whereas other spectral frequencies were only transiently affected in the frontal cortex, reticular formation, and striatum.
In conclusion, this study demonstrated that the low-dose medication Neurexan influences central nervous system activity in rats. The resulting electroencephalographic profile of Neurexan shows several similarities with those of other calming agents, such as Valeriana and Passiflora, suggesting a potential benefit of Neurexan for patients with stress-related disorders. Moreover, this report demonstrates that electroencephalographic signatures are also valid biomarkers for the assessment of low-dose medications, such as Neurexan.
- Somers JM, Goldner EM, Waraich P, Hsu L: Prevalence and incidence studies of anxiety disorders: a systematic review of the literature. Can J Psychiatry 2006, 51:100–113.
- Strine TW, Chapman DP: Associations of frequent sleep insufficiency with health-related quality of life and health behaviors. Sleep Med 2005, 6:23–27. CrossRef
- Rosenberg RP: Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies. Ann Clin Psychiatry 2006, 18:49–56. CrossRef
- Cascade E, Kalali AH, Kennedy SH: Real-world data on SSRI antidepressant side effects. Psychiatry (Edgmont) 2009, 6:16–18.
- O'brien CP: Benzodiazepine use, abuse, and dependence. J Clin Psychiatry 2005,66(Suppl 2):28–33.
- Dawson DA, Grant BF, Ruan WJ: The association between stress and drinking: modifying effects of gender and vulnerability. Alcohol Alcohol 2005, 40:453–460.
- Lakhan SE, Vieira KF: Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review. Nutr J 2010, 9:42. CrossRef
- Meeks TW, Wetherell JL, Irwin MR, Redwine LS, Jeste DV: Complementary and alternative treatments for late-life depression, anxiety, and sleep disturbance: a review of randomized controlled trials. J Clin Psychiatry 2007, 68:1461–1471. CrossRef
- Heel GmbH: Neurexan Package Insert. Heel GmbH, Baden-Baden,Germany; 2004.
- Akhondzadeh S, Naghavi HR, Vazirian M, Shayeganpour A, Rashidi H, Khani M: Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with Oxazepam. J Clin Pharm Ther 2001, 26:363–367. CrossRef
- Movafegh A, Alizadeh R, Hajimohamadi F, Esfehani F, Nejatfar M: Preoperative oral Passiflora incarnata reduces anxiety in ambulatory surgery patients: a double-blind, placebo-controlled study. Anesth Analg 2008, 106:1728–1732. CrossRef
- Bourin M, Bougerol T, Guitton B, Broutin E: A combination of plant extracts in the treatment of outpatients with adjustment disorder with anxious mood: controlled study versus placebo. Fundam Clin Pharmacol 1997, 11:127–132. CrossRef
- Connor J, Connor T, Marshall PB, Reid A, Turnbull MJ: The pharmacology of Avena sativa. J Pharm Pharmacol 1975, 27:92–98. CrossRef
- Ruiz-Vega G, Perez-Ordaz L, Cortes-Galvan L, Juarez G: A kinetic approach to caffeine-Coffea cruda interaction. Homeopathy 2003, 92:19–29. CrossRef
- Kröz M, Anders S, Brauer D, Zerm R, Schad F, Girke M: Valerianate of Zinc in Restless Legs Syndrome: A Retrospective Analysis [in German]. Erfahrungsheilkunde 2009, 58:121–129. CrossRef
- Waldschutz R, Klein P: The homeopathic preparation Neurexan vs. valerian for the treatment of insomnia: an observational study. ScientificWorldJournal 2008, 8:411–420. CrossRef
- Hubner R, Klein P, van HR: Effectiveness of the homeopathic preparation Neurexan compared with that of commonly used valerian-based preparations for the treatment of nervousness/restlessness - an observational study. ScientificWorldJournal 2009, 9:733–745. CrossRef
- Leiser SC, Dunlop J, Bowlby MR, Devilbiss DM: Aligning strategies for using EEG as a surrogate biomarker: a review of preclinical and clinical research. Biochem Pharmacol 2011, 81:1408–1421. CrossRef
- Kuhlmann J, Wensing G: The applications of biomarkers in early clinical drug development to improve decision-making processes. Curr Clin Pharmacol 2006, 1:185–191. CrossRef
- Dimpfel W: Pharmacological modulation of cholinergic brain activity and its reflection in special EEG frequency ranges from various brain areas in the freely moving rat (Tele-Stereo-EEG). Eur Neuropsychopharmacol 2005, 15:673–682. CrossRef
- Dimpfel W, Spuler M, Koch R, Schatton W: Radioelectroencephalographic comparison of memantine with receptor-specific drugs acting on dopaminergic transmission in freely moving rats. Neuropsychobiology 1987, 18:212–218. CrossRef
- Dimpfel W, Schober F: Norepinephrine, EEG theta waves and sedation in the rat. Brain Pharmacology 2001, 1:89–97.
- Sebban C, Zhang XQ, Tesolin-Decros B, Millan MJ, Spedding M: Changes in EEG spectral power in the prefrontal cortex of conscious rats elicited by drugs interacting with dopaminergic and noradrenergic transmission. Br J Pharmacol 1999, 128:1045–1054. CrossRef
- Dimpfel W: Preclinical data base of pharmaco-specific rat EEG fingerprints (tele-stereo-EEG). Eur J Med Res 2003, 8:199–207.
- Council of Europe, European Pharmacopoeia Commission European Directorate for the Quality of Medicines & Healthcare: European Pharmacopoeia. Council of Europe, Strasbourg; 2010.
- Reagan-Shaw S, Nihal M, Ahmad N: Dose translation from animal to human studies revisited. FASEB J 2008, 22:659–661. CrossRef
- Paxinos G, Watson C: The rat brain in stereotactic coordinates. Academic Press, New York; 1982.
- Dimpfel W, Spuler M, Nickel B: Radioelectroencephalography (Tele-Stereo-EEG) in the rat as a pharmacological model to differentiate the central action of flupirtine from that of opiates, diazepam and phenobarbital. Neuropsychobiology 1986, 16:163–168. CrossRef
- Dimpfel W, Koch K, Weiss G: Early effect of NEURAPAS(R) balance on current source density (CSD) of human EEG. BMC Psychiatry 2011, 11:123. CrossRef
- Baghdoyan HA, Monaco AP, Rodrigo-Angulo ML, Assens F, McCarley RW, Hobson JA: Microinjection of neostigmine into the pontine reticular formation of cats enhances desynchronized sleep signs. J Pharmacol Exp Ther 1984, 231:173–180.
- Bourgin P, Escourrou P, Gaultier C, Adrien J: Induction of rapid eye movement sleep by carbachol infusion into the pontine reticular formation in the rat. Neuroreport 1995, 6:532–536. CrossRef
- Shiromani PJ, Fishbein W: Continuous pontine cholinergic microinfusion via mini-pump induces sustained alterations in rapid eye movement (REM) sleep. Pharmacol Biochem Behav 1986, 25:1253–1261. CrossRef
- Dimpfel W: Pharmacological modulation of dopaminergic brain activity and its reflection in spectral frequencies of the rat electropharmacogram. Neuropsychobiology 2008, 58:178–186. CrossRef
- Leathwood PD, Chauffard F, Heck E, Munoz-Box R: Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man. Pharmacol Biochem Behav 1982, 17:65–71. CrossRef
- Leathwood PD, Chauffard F: Aqueous extract of valerian reduces latency to fall asleep in man. Planta Med 1985, 2:144–148. CrossRef
- Dorn M: Efficacy and tolerability of Baldrian versus Oxazepam in non-organic and non-psychiatric insomniacs: a randomized, double-blind, clinical, comparative study [in German]. Forsch Komplementar med Klass Naturheilkd 2000, 7:79–84. CrossRef
- Ziegler G, Ploch M, Miettinen-Baumann A, Collet W: Efficacy and tolerability of valerian extract LI 156 compared with Oxazepam in the treatment of non-organic insomnia–a randomized, double-blind, comparative clinical study. Eur J Med Res 2002, 7:480–486.
- Vonderheid-Guth B, Todorova A, Brattström A, Dimpfel W: Pharmacodynamic effects of valerian and hops extract combination (Ze 91019) on the quantitative-topographical EEG in healthy volunteers. Eur J Med Res 2000, 5:139–144.
- Dhawan K, Kumar S, Sharma A: Anti-anxiety studies on extracts of Passiflora incarnata Linneaus. J Ethnopharmacol 2001, 78:165–170. CrossRef
- Basta M, Chrousos GP, Vela-Bueno A, Vgontzas AN: Chronic insomnia and stress system. Sleep Med Clin 2007, 2:279–291. CrossRef
- Schulz H, Jobert M, Hübner WD: The quantitative EEG as a screening instrument to identify sedative effects of single doses of plant extracts in comparison with diazepam. Phytomedicine 1998, 5:449–458. CrossRef
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/12/126/prepub
- Effect of Neurexan on the pattern of EEG frequencies in rats
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
BMC Complementary and Alternative Medicine
- Online Date
- August 2012
- Online ISSN
- BioMed Central
- Additional Links
- Central nervous system
- Stress-related disorders
- Brain waves